Drug intelligence / Profile preview

cellopolysaccharide + probiotics

Development stage: Unknown
Lead developer: First Affiliated Hospital, Zhejiang University School of Medicine
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Rectal

Overview

cellopolysaccharide + probiotics is an investigational combination therapy developed by the First Affiliated Hospital, Zhejiang University, specifically for the treatment of diversion colitis. Diversion colitis is an inflammatory condition that occurs in segments of the colon that have been surgically excluded from the fecal stream, leading to a localized deficiency of short-chain fatty acids (SCFAs). The therapy consists of a cell-wall-derived polysaccharide (acting as a prebiotic) and a probiotic mixture, typically containing strains such as *Bifidobacterium*, *Lactobacillus*, and *Enterococcus*. When administered rectally as a retention enema, the probiotics ferment the polysaccharide to produce SCFAs, particularly butyrate, which provide essential energy to the colonic mucosa and exert anti-inflammatory effects. This approach aims to restore the local microenvironment and promote mucosal healing in the diverted bowel segment.

Other names: cell polysaccharide + probioticscell polysaccharide and probiotics

Beyond the preview

Go deeper on cellopolysaccharide + probiotics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cellopolysaccharide + probiotics.

Explore the full profile